Madam Therapeutics

Our Pipeline

We have ambitious long-term plans with our company: the number of products that can be developed based on the SAAPs is large: basically any type of indication where bacterial infections play a role can be targeted.

Our strategy is to continuously develop products up-to and including clinical proof of concept, after which we partner them with the best partner to get the product towards patients worldwide. Our aim is to alleviate the burden of bacterial infections for patients worldwide, as well as for the global healthcare system including all its stakeholders.